FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washing

-t D.C. 20E40	F
gton, D.C. 20549	ء اا
•	
	11 C

	OMB APPROVAL							
	OMB Number:	3235-0287						
	Estimated average burden							
-	hours nor resnance.	0.5						

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Hackman Jeffrey S.				2. Issuer Name and Ticker or Trading Symbol Comera Life Sciences Holdings, Inc. CMRA						RA (Che	Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner					
(Last) (First) (Middle) C/O COMERA LIFE SCIENCES HOLDINGS, INC.				3. Date of Earliest Transaction (Month/Day/Year) 09/27/2023						X	X Officer (give title below) See Rem.			Other (specification) S.	pecify	
12 GILL STREET, SUITE 4650					4. If Amendment, Date of Original Filed (Month/Day/Year)					6. Inc	6. Individual or Joint/Group Filing (Check Applicable Line)					
(Street) WOBUR	N M	Ά	01801)	_	ting Person One Reporti	ing		
(City)	(S		(Zip)		Rule 10b5-1(c) Transaction Indication Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10. attive Securities Acquired, Disposed of, or Beneficially Owned											
1. Title of Security (Instr. 3) 2. Transa Date (Month/D.					2A. Deemed Execution Date,		3. Transacti Code (Ins	3. Transaction Code (Instr. 8) 4. Securities Acquired (A Disposed Of (D) (Instr. 3.		ed (A) or str. 3, 4 and 5	or Securities Beneficially Owned Follo Reported		Form:	: Direct I r Indirect I str. 4) (7. Nature of Indirect Beneficial Ownership (Instr. 4)	
			Table II - D					uired, Dis	posed of	or Ben	eficially ((Instr. 3 a				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security		3A. Deemed Execution Date, if any (Month/Day/Year)	Cod	saction e (Instr.	Derivative		Expiration Date of (Month/Day/Year) Un		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Cod	e V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		(Instr. 4)	on(s)		
Stock Option (Right to Purchase)	\$0.376	09/27/2023		A		600,000		(1)	09/27/2033	Common Stock	600,000	\$0	600,00	00	D	

Explanation of Responses:

1. 25% of the shares underlying the stock option vest on September 27, 2024, with the remaining shares vesting on a monthly basis on the 27th day of each month thereafter, in each case, subject to continuous service to the issuer, such that the option shall be fully vested on September 27, 2027.

Chairman, President, and Chief Executive Officer.

/s/ Ryan M. Rourke Reed, 09/28/2023 Attorney-in-Fact

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.